Longeveron Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Longeveron Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $709.0K | Feb 27, 2024 |
| FY2023 | Dec 31, 2022 | $1.22M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.31M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $5.63M | Mar 11, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.39M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $709.0K | Feb 28, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $803.0K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.88M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $221.0K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $497.0K | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $590.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.83M | Mar 11, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.70M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($15.97M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($21.41M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($18.84M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($17.05M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($3.72M) | Mar 11, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.29M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($16.52M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($21.03M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($18.04M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($17.46M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($3.78M) | Mar 11, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.04M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $8.14M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $9.07M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $9.37M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $7.09M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.67M | Mar 11, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.65M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($13.87M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($19.00M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($13.97M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($9.64M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.36M) | Mar 11, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $245.0K | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $655.0K | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $301.0K | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $569.0K | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $330.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $131.0K | Mar 11, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.26M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $25.56M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $12.08M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $27.41M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $42.77M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $9.24M | Mar 11, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.59M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.67M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.34M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $6.91M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $5.31M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $7.28M | Mar 11, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.68M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $21.89M | Mar 17, 2026 |
| FY2025 | Dec 31, 2023 | $6.74M | Mar 17, 2026 |
| FY2024 | Dec 31, 2022 | $20.50M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $37.45M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $1.96M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $4.4K | Mar 11, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($132.31M) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | ($109.61M) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | ($84.98M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($62.77M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($43.94M) | Mar 14, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.66M | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | $19.23M | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | $4.95M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $10.50M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $25.66M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $816.0K | Mar 11, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $311.0K | Mar 11, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (10) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 17, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 17, 2026 |
| FY2024 | Dec 31, 2023 | (10) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |